文献速递消化系统肿瘤

阿帕替尼联合新辅助化疗后手术对局部晚期胃腺癌病理缓解的影响:单臂开放标签II期试验

Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial.
PubMed 文献 · Eur J Cancer · 2020-03-11

该单臂II期试验评估SOXA方案(替吉奥+奥沙利铂+阿帕替尼)新辅助治疗局部晚期胃腺癌的疗效与安全性。29例初治患者接受3周期化疗和2周期阿帕替尼后手术,病理缓解率89.7%(95%CI 72.7%-97.8%,P<0.001),客观缓解率79.3%,R0切除率96.6%,病理完全缓解率13.8%,≥III级不良事件34.5%。

要点

  • SOXA新辅助方案在局部晚期胃腺癌中病理缓解率达89.7%
  • R0切除率96.6%,病理完全缓解率13.8%,55.2%患者TNM降期
  • ≥III级不良事件发生率34.5%,无治疗相关死亡,安全性可控

核心结论

  • SOXA方案新辅助治疗后手术在局部晚期胃腺癌中显示出良好疗效和可控的安全性。

研究设计与样本

  • 单臂、开放标签、II期临床试验,纳入29例初治局部晚期胃腺癌患者。
  • 术前接受3周期替吉奥+奥沙利铂和2周期阿帕替尼治疗,随后手术。
  • 主要终点为病理缓解率(pRR)。

主要发现

  • 病理缓解率89.7%(95%CI 72.7%-97.8%;26/29例;P<0.001),28例接受手术。
  • 客观缓解率79.3%(95%CI 60.3%-92.0%),疾病控制率96.6%(95%CI 82.2%-99.9%)。
  • R0切除率96.6%(95%CI 82.2%-99.9%),病理完全缓解率13.8%(95%CI 1.2%-26.3%)。
  • 16例(55.2%)患者出现TNM分期降期。
  • 新辅助治疗期间10例(34.5%)发生≥III级不良事件,无治疗相关死亡;手术相关并发症12/28例(42.9%)。

临床怎么用

  • SOXA方案可作为局部晚期胃腺癌新辅助治疗的潜在选择,但需随机对照试验进一步验证。
  • 治疗期间需关注≥III级不良事件及手术相关并发症。

局限性

  • 单臂设计、样本量小(29例),无对照组,结论需随机试验证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The evidence of combining neoadjuvant chemotherapy with targeted therapy for patients with locally advanced gastric cancer is inadequate. We conducted a single-arm phase II trial to evaluate the efficacy and safety of S-1, oxaliplatin and apatinib (SOXA) in patients with locally advanced gastric adenocarcinoma. METHODS: Treatment-naïve patients received three preoperative cycles of S-1 (80-120 mg/day on days 1-14) and oxaliplatin (130 mg/m2 on day 1) and two cycles of apatinib (500 mg/day for 21 days) at 3-week intervals, followed by surgery. The primary end-point was pathologic response rate (pRR). This trial is registered at ChiCTR.gov.cn: ChiCTR-OPC-16010061. RESULTS: Of 29 patients included, median age was 60 (range, 43-73) years; 20 (69.0%) were male. The pRR was 89.7% (95% confidence interval [CI], 72.7%-97.8%; 26 of 29 patients; P < 0.001) with 28 patients treated with surgery. All 29 patients were available for preoperative response evaluation, achieving an objective response rate of 79.3% (95% CI, 60.3%-92.0%) and a disease control rate of 96.6% (95% CI, 82.2%-99.9%). The margin-free resection rate was 96.6% (95% CI, 82.2%-99.9%). The pathologic complete response rate was 13.8% (95%CI, 1.2%-26.3%). Downstaging of overall TNM stage was observed in 16 (55.2%) patients. During neoadjuvant therapy, 10 (34.5%) patients had grade ≥III adverse events. No treatment-related death occurred. Surgery-related complications were observed in 12 of 28 (42.9%) patients. CONCLUSION: SOXA followed by surgery in patients with locally advanced gastric adenocarcinoma showed favourable activity and manageable safety. A randomised controlled trial in locally advanced gastric or oesophagogastric junction adenocarcinoma is ongoing (ClinicalTrials.gov: NCT04208347).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Zheng Y, Yang X, Yan C, et al. Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial. Eur J Cancer. 2020. PMID: 32171104. doi:10.1016/j.ejca.2020.02.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。